Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium, Apr. 11 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD [...]
Paris, France and Cambridge, Massachusetts, USA, Jun. 4 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO. Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience [...]
LONDON, Jan. 7 (Korea Bizwire) – Ascension Healthcare plc (“Ascension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis is pleased to announce the appointment of Dr Gavin Ling as Chief Medical Officer. Biresh Roy, Chief Executive Officer of Ascension said: “We are delighted to have [...]
Alcester, Warwickshire, UK, Jan. 4 (Korea Bizwire) - Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announces that the Company has appointed Dr. Paul Komenda as Chief Medical Officer. Dr. Komenda, Associate Professor of Medicine at the University of Manitoba, is a [...]
NEW YORK, Dec. 6 (Korea Bizwire) — Druggability Technologies USA today announced that Dr. John E. Friend II has been named as Chief Medical Officer. Druggability Technologies USA has been engaged by Druggability Technologies Holding (DRGT) to assist with the clinical development of all human trials for DRGT. DRGT is a specialty pharmaceutical company that [...]
GERMANTOWN, Md., Nov. 8 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, MD, FACR, FACP, as Chief Medical Officer. “Given his extensive experience in the biopharma industry, Dr. Recker brings to Neuralstem an expertise that will be critical to the [...]